405results about How to "Good clinical value" patented technology

The invention relates to a DTI (Diffusion Tensor Imaging)-based cranial nerve fiber bundle three-dimensional rebuilding method and a method of manufacturing a head three-dimensional model comprising nerve fiber bundles based on a 3D printing technology. The method comprises the following steps: magnetic resonance scanning is carried out on a target tissue area and surrounding nerve fiber bundles to acquire MRI image data for the target tissue area comprising the nerve fiber bundles; DTI processing and related processing are carried out on the acquired MRI image to acquire an MRI image with an identifiable nerve fiber bundle; calculation is carried out on X-axis information, Y-axis information and Z-axis information of the MRI image with the identifiable nerve fiber bundle, three-dimensional rebuilding is carried out via mimics software, and a three-dimensional mode comprising the cranial nerve fiber bundle is acquired. Through the three-dimensional model and the 3D printing three-dimensional solid model, the position relation among an anatomic structure, a brain function area and each tissue can be displayed clearly, a solid model is provided for an operation, and the method is used for operation approach design and operation simulation.

The invention belongs to the field of medical apparatuses and instruments, and in particular discloses a gait rehabilitation robot and a method for controlling the gait rehabilitation robot. The method comprises the following steps: according to a wearable sensor system, measuring a two-dimensional lower limb posture of a user in real time during walking, calculating the walking speed of the user, and controlling the operating speed of the robot according to the walking speed. The method is convenient to use and low in cost and is not limited by the site, and the gait rehabilitation robot can well follow the walking speed and gait characteristics of the user, so that the aim of helping the user to walk is achieved, secondary injury to the user can be avoided, and the gait rehabilitation robot has high reliability and excellent popularization prospects.

The invention provides an miRNA marker associated with genomic stability of human umbilical cord blood mesenchymal stem cells and a detection method of the miRNA marker. A new generation of high-throughput sequencing technology is used, in combination with a bioinformatic analysis method of a system, to screen and obtain the miRNA associated with genomic stability of human umbilical cord blood mesenchymal stem cells, wherein an RNA sequence is shown in SEQ IDNO.1-5. The invention also provides a specific primer for detecting the miRNA and a detection method of the specific primer, wherein conditions for the detection method of human umbilical cord blood mesenchymal stem cells are optimized. Through the detection of the specific miRNA marker provided by the invention, the genomic stability of human umbilical cord blood-derived mesenchymal stem cells after passage or amplification can be estimated effectively, to reduce costs and the risk of subsequent clinical application; the miRNA has excellent clinical application value and broad application prospect.

The invention discloses polysaccharide biomedical colloid. The colloidal fluid is prepared from, by weight, 0.5-10% of sodium carboxymethyl cellulose, 0.5-1.5% of sodium chloride, 0.5-1.5% of carbomer, 0.08-0.7% of sodium hyaluronate, 0.01-0.05% of phytate, 0.02-0.1% of sodium alginate, 0.1-0.3% of glycerol, 0.15-0.45% of chitobiose, 0.15-0.35% of polyhexamethylene guanidine, 0.01-0.2% of liquorices extract and the balance water used for injection. By means of formula optimization, the polysaccharide biomedical colloid is free of toxic and side effects, has great clinical application value, is short in healing time and high in healing rate, forms a wound surface wet environment, can directly restrain scar forming when used for cell repairing, and can form a wound surface protection film, block injuries caused by bacteria to wound surfaces, and restrain the adsorption process, the multiplication process, the copying process and other processes of bacteria on wound surfaces.

The invention discloses a double labelling Nano-Au probe and a preparation method and application thereof. The probe comprises a Nano-Au particle as a core, the surface of which is connected with antibody and oligonucleotide simultaneously. The preparation method of the double labelling Nano-Au probe includes the following steps: (1) coupled reaction: adding oligonucleotide solution and antibody solution in Nano-Au sol with certain concentration and uniformly mixing the solutions to lead the Nano-Au particle, the antibody and nucleic acid to fully act in the solution; and (2) stabilizing and blocking reaction: preparing PBS buffer solution with the content of SDS being 5-10 percent and then adding the PBS buffer solution in the mixed solution prepared in step (1) and adding sealant to form nano probe sol. The double labelling Nano-Au probe can convert the antigenic detection into the detection of nucleic acid matter and is applied to the detection of tumor marker, hormone and pathogene micro-protein.

The invention relates to a serum exosome miRNA biological marker and a kit for early diagnosis of gastric cancer. The serum exosome miRNA biological marker consists of miR-19b and miR-106a. The serum exosome miRNA biological marker uses serum exosomes miRNA, especially two miRNA (hsa-MiR-19b-3p united hsa-miR-106a-5p) closely relevant with a gastric cancer serve as gastric-cancer early diagnosis markers, and the marker is superior to clinic means such as an existing gastroscope in early diagnosis and has better specificity and sensitivity. The kit consists of a specific amplification primer and a general PCR amplification reagent, has a good clinical application value in early diagnosis of the gastric cancer and provides a new thinking and method for improvement of the early diagnosis level of the gastric cancer.

The invention discloses a non-natural amino acid modified endomorphin-1 analogue. A synthesis method comprises the following step: replacing amino acid phenylalanine at a fourth site from a terminal N to a terminal C of parent endomorphin-1 by respectively using 2-thienyl substituted alpha-alkenyl-beta-amino acid and 3-thienyl substituted alpha-alkenyl-beta-amino acid. The affinity and enzymatic hydrolysis stability of a mu opioid receptor of the non-natural amino acid modified endomorphin-1 analogue can be effectively improved, and thus the in-vivo analgesic effect of the non-natural amino acid modified endomorphin-1 analogue can be further improved and prolonged; and the non-natural amino acid modified endomorphin-1 analogue is subjected to pharmacological activity identification by virtue of radioligand receptor binding experiments, in-vitro organ biological assays and in-vitro enzymatic hydrolysis stability and warm bath tail-flick analgesic experiments, and results show that compared with parent endomorphin-1, the synthesized non-natural amino acid modified endomorphin-1 analogue disclosed by the invention has higher affinity, higher enzymatic hydrolysis stability and higher analgesic activity, and has potential application values of being taken as clinical polypeptide analgesic medicines.